CUSIP 252828108 · who reports it, how much, and how much it matters to them
44 of the 720 hedge fund managers we track reported shares of Dianthus Therapeutics, Inc. (Nasdaq: DNTH) on Form 13F for 30 June 2026. Between them they reported USD 1.2bn. The largest position belongs to Fairmount Funds Management, at USD 247m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Fairmount Funds Management2 funds on PPLI.com | USD 247m | 16.3% |
| 2 | Octagon Capital Advisors1 fund on PPLI.com | USD 180m | 16.1% |
| 3 | Polar Capital LLP26 funds on PPLI.com | USD 99m | 0.2% |
| 4 | Citadel Advisors32 funds on PPLI.com | USD 95m | 0.0% |
| 5 | Baker Bros. Advisors2 funds on PPLI.com | USD 83m | 0.4% |
| 6 | Logos Global Management1 fund on PPLI.com | USD 78m | 3.4% |
| 7 | Cormorant Asset Management1 fund on PPLI.com | USD 73m | 3.7% |
| 8 | Braidwell12 funds on PPLI.com | USD 58m | 2.1% |
| 9 | Artisan Partners1 fund on PPLI.com | USD 25m | 0.0% |
| 10 | RTW Investments2 funds on PPLI.com | USD 24m | 0.2% |
| 11 | LMR Partners2 funds on PPLI.com | USD 22m | 0.1% |
| 12 | Samlyn Capital8 funds on PPLI.com | USD 19m | 0.3% |
| 13 | Adage Capital Management1 fund on PPLI.com | USD 18m | 0.0% |
| 14 | Atika Capital Management3 funds on PPLI.com | USD 16m | 1.1% |
| 15 | Artia Global Partners1 fund on PPLI.com | USD 16m | 2.9% |
| 16 | Balyasny Asset Management25 funds on PPLI.com | USD 16m | 0.0% |
| 17 | Eagle Health Investments1 fund on PPLI.com | USD 13m | 2.1% |
| 18 | Marshall Wace LLP84 funds on PPLI.com | USD 13m | 0.0% |
| 19 | PFM Health Sciences3 funds on PPLI.com | USD 12m | 1.0% |
| 20 | Orbimed Advisors1 fund on PPLI.com | USD 11m | 0.2% |
| 21 | Two Sigma Investments35 funds on PPLI.com | USD 10m | 0.0% |
| 22 | Millennium Management6 funds on PPLI.com | USD 9m | 0.0% |
| 23 | Sio Capital Management4 funds on PPLI.com | USD 5.8m | 1.0% |
| 24 | HighVista Strategies27 funds on PPLI.com | USD 5m | 1.1% |
| 25 | Burkehill Global Management5 funds on PPLI.com | USD 4.9m | 0.2% |
| 26 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 4.2m | 0.0% |
| 27 | D. E. Shaw & Co.15 funds on PPLI.com | USD 4.2m | 0.0% |
| 28 | Verition Fund Management3 funds on PPLI.com | USD 3.9m | 0.0% |
| 29 | Tudor Investment Corporation10 funds on PPLI.com | USD 3.6m | 0.0% |
| 30 | Atom Investors1 fund on PPLI.com | USD 3.6m | 0.3% |
| 31 | Hudson Bay Capital Management8 funds on PPLI.com | USD 3.5m | 0.0% |
| 32 | Aquatic Capital Management3 funds on PPLI.com | USD 2.4m | 0.1% |
| 33 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 2m | 0.1% |
| 34 | Rock Springs Capital Management2 funds on PPLI.com | USD 2m | 0.1% |
| 35 | Brevan Howard Capital Management39 funds on PPLI.com | USD 1.8m | 0.0% |
| 36 | Walleye Capital8 funds on PPLI.com | USD 1.7m | 0.0% |
| 37 | Cinctive Capital Management5 funds on PPLI.com | USD 1.3m | 0.0% |
| 38 | Engineers Gate Manager1 fund on PPLI.com | USD 1.1m | 0.0% |
| 39 | Verdad Advisers6 funds on PPLI.com | USD 981,000 | 0.9% |
| 40 | Boothbay Fund Management2 funds on PPLI.com | USD 723,000 | 0.0% |
| 41 | Persistent Asset Partners10 funds on PPLI.com | USD 543,000 | 0.2% |
| 42 | Entrypoint Capital1 fund on PPLI.com | USD 413,000 | 0.1% |
| 43 | Capstone Investment Advisors25 funds on PPLI.com | USD 207,000 | 0.0% |
| 44 | Bayforest Capital1 fund on PPLI.com | USD 196,000 | 0.2% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Fairmount Funds Management | USD 247m | 16.3% |
| 2 | Octagon Capital Advisors | USD 180m | 16.1% |
| 3 | Cormorant Asset Management | USD 73m | 3.7% |
| 4 | Logos Global Management | USD 78m | 3.4% |
| 5 | Artia Global Partners | USD 16m | 2.9% |
| 6 | Braidwell | USD 58m | 2.1% |
| 7 | Eagle Health Investments | USD 13m | 2.1% |
| 8 | HighVista Strategies | USD 5m | 1.1% |
| 9 | Atika Capital Management | USD 16m | 1.1% |
| 10 | PFM Health Sciences | USD 12m | 1.0% |
Dianthus Therapeutics, Inc. trades under the symbol DNTH on the Nasdaq. Its CUSIP, the code used on Form 13F, is 252828108.
44 of the 720 hedge fund managers PPLI.com tracks reported Dianthus Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Fairmount Funds Management (USD 247m), Octagon Capital Advisors (USD 180m), Polar Capital LLP (USD 99m), Citadel Advisors (USD 95m) and Baker Bros. Advisors (USD 83m).
44 managers in our coverage reported it, and between them they run 480 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Fairmount Funds Management, where the position was 16.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Dianthus Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.